Navigation Links
Launch of IMIDIA - An Innovative Medicines Initiative Project for Diabetes

FRANKFURT, Germany and LAUSANNE, Switzerland and PARIS, June 14, 2010 /PRNewswire-FirstCall/ -- IMIDIA ("Innovative Medicines Initiative for Diabetes"), a public private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a project focusing on pancreatic islet cell function and survival. Academia, biotech and pharma industry have joined forces to develop biomarkers and tools to pave the way for improved disease management and ultimately provide a cure for diabetes.

Leading European experts from 14 academic institutions, 8 pharmaceutical research organizations and 1 biotech company in the area of pancreatic ss-cells (= the body's own insulin producing cells) officially launched the IMIDIA project. The project is supported by the Innovative Medicines Initiative (IMI). IMI a unique Public Private Partnership between the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations / EFPIA) and the European Union. The EU contributes a total of EUR 1 billion over ten years, which is matched in-kind by the EFPIA member companies.

IMIDIA is an important stepping stone in the development of better tools, biomarkers and understanding to enable the development of ss-cell medicines - a key to an ultimate long-term vision: the cure for diabetes. This pandemic disease of the 21st century currently affects 285 million people worldwide. It is anticipated that this number will rise sharply to affect 439 million people worldwide by 2030 in particular spreading to the younger population.

IMIDIA is a unique collaboration of leading research groups in Europe focusing on the necessary innovation tightly coupled with the applications and evaluation of these results to develop new diagnostics, prognostics and therapeutics. Around 100 researchers operating in 6 different scientific work packages will focus on novel approaches e.g. imaging biomarkers, systems biology and pathway analysis with the goal of developing patient relevant disease models in vitro and in vivo as well as biomarkers to monitor disease progression and treatment.

"It has been fascinating to see how a powerful consortium has been formed starting from the different worlds of academic research and the pharmaceutical industry research organizations," Werner Kramer from sanofi-aventis, Bernard Thorens from University of Lausanne and Alain Ktorza from Servier, the "Triumvirate" coordinating IMIDIA, agree. "Guided by a sustainable win-win situation for all participants, the collaborative spirit coupled with the free flow of information and data within the IMIDIA project teams will support us - the IMIDIA team - in our endeavour to reach these ambitious goals."


The IMIDIA team, led by sanofi-aventis, Servier and the University of Lausanne is working on the generation of novel, patient centric tools, biomarkers, and fundamental knowledge on ss-cell organization to accelerate the path to improved diabetes management.

The scientific program aims at delivering:

Novel tools for the study of human ss-cell development, function and survival; their modulation by potential therapeutic compounds; and for in vivo ss-cell imaging.

Biomarkers for the diagnosis and prognosis of ss-cell failure and for monitoring diabetes progression and treatment.

Knowledge on novel pathways and sites that control ss-cell proliferation, differentiation and apoptosis, and on the role of known nutrient regulated pathways and sites in controlling ss-cell mass and function.

IMIDIA participants are AstraZeneca, Boehringer Ingelheim, the French Atomic Energy Commission (CEA), Hannover Medical School (MHH), Imperial College London, Lilly, the National Centre for Scientific Research (CNRS), the National Institute of Health and Medical Research (INSERM), Novartis, Novo Nordisk, Roche, sanofi-aventis, Sarl Endocells, Servier, SIB Swiss Institute of Bioinformatics, Vrije University of Brussels, Dresden University of Technology, University of Geneva, University of Lausanne, University Paris Diderot, University of Pisa.

The close collaboration of academic teams, pharmaceutical companies and biotechs is providing unique levels of expertise and is forming a strong basis to reach the IMIDIA project goals.

For further details - please visit:

About IMI:

The Innovative Medicines Initiative is a unique Public Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission.

IMI's overall goal is to make Europe again the world leader in pharmaceutical research for the benefit of the economy and society, by removing research bottlenecks in the current drug development process.

For further details - please visit:

SOURCE Sanofi-aventis R&D
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
3. BioSpace and BayBio Launch 11th Edition of Biotech Bay(TM) Hotbed Map Campaign
4. Novozymes Launches Enzyme to Reduce Acrylamide in Food
5. Enova Medical Launches Exos Corporation
6. Nitec Pharma AG Announces Appointments of CEO & CFO in Preparation for Launch of Lodotra(R)
7. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
8. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
9. Concuity Announces the Launch of Its New Fully Accessible Website - Concuity.Com
10. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
11. Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):